SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Event Reported): April 28, 1997
AGOURON PHARMACEUTICALS, INC.
---------------------------------
(Exact name of registrant as specified in its charter)
California 0-15609 33-0061928
-------------- ----------- ------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification Number)
10350 North Torrey Pines Road 92037
La Jolla, California
---------------------------------------------------------------------------
(Address of principal executive offices) Zip Code
(619) 622-3000
----------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Item 5. Other Events.
On April 28, 1997, the Registrant signed a definitive agreement to
acquire Alanex Corporation, a privately held drug discovery company, for
1,000,000 shares of newly issued Agouron common stock. The transaction is
expected to close in approximately thirty (30) days. See the Press Release
attached as Exhibit 99.2.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit Number
99.2 Form of Press Release dated April 29, 1997.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: May 2, 1997
AGOURON PHARMACEUTICALS, INC.
By /s/ Peter Johnson
----------------------------
Peter Johnson
President and
Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
99.2 Form of Press Release dated April 29, 1997.